Daniel Y.C. Heng

University of Calgary — Canada

Medicine · Health Sciences

55h-index17.8kcitations223works9.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(192), Renal and related cancers(114), Cancer Genomics and Diagnostics(88), Cancer Immunotherapy and Biomarkers(39), Pancreatic and Hepatic Oncology Research(23)

Publications222 total

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers
UNC Libraries·2025Open Access
50Clinical characteristics, determinants and subsequent therapy of primary refractory metastatic renal cell carcinoma (mRCC): an international metastatic database consortium (IMDC) study
The Oncologist·2025Open Access
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review
Cancer Treatment Reviews·2025· 1 citedOpen Access
CABOSEQ 3—Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Clinical Genitourinary Cancer·2025· 1 citedOpen Access
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors
JCO Oncology Practice·2025· 1 cited
MP02-05 MULTI-INSTITUTIONAL VALIDATION STUDY OF THE KIDNEY CANCER RISK EQUATION (KCRE): RESULTS FROM THE CANADIAN KIDNEY CANCER INFORMATION SYSTEM (CKCis)
The Journal of Urology·2025
Optimal Timing of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Considering Sarcomatoid Status: A Real-World Study
Clinical Genitourinary Cancer·2025· 1 cited
Development and first-in-human CAR T therapy against the pathognomonic MiT-fusion driven protein GPNMB
2025· 2 citedOpen Access
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma
Nature Cancer·2025· 17 citedOpen Access
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis
European Urology Oncology·2024· 1 citedOpen Access
Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?
British Journal of Urology·2024· 3 citedOpen Access
Validation of Prognostic Models for Renal Cell Carcinoma Recurrence, Cancer-Specific Mortality, and All-Cause Mortality
The Journal of Urology·2024· 1 cited
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
The Lancet·2024· 56 citedOpen Access
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma
Journal of Clinical Oncology·2024· 30 citedOpen Access
Potential of neutrophil-to-eosinophil ratio as a new prognostic tool for patients with advanced renal cell carcinoma receiving first-line immuno-oncology combinations
BMJ Oncology·2024Open Access
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
The Lancet Oncology·2024· 65 citedOpen Access
Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative review
Expert Review of Anticancer Therapy·2024· 7 cited
Impact of smoking status on clinical outcomes in patients with metastatic renal cell carcinoma treated with first-line immune checkpoint inhibitor-based regimens
The Oncologist·2024· 5 citedOpen Access
MP51-17 NATURAL HISTORY OF PATIENTS WITH REGIONAL LYMPH NODE POSITIVE RENAL CELL CARCINOMA: RESULTS FROM THE CANADIAN KIDNEY CANCER COLLABORATION
The Journal of Urology·2024
Reply to Yudai Ishiyama and Fumihiko Urabe’s Letter to the Editor re: Kosuke Takemura, Audreylie Lemelin, Matthew S. Ernst, et al. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.01.006
European Urology·2024· 1 cited
page 1 of 12Next →

Frequent Co-authors

Toni K. Choueiri(36), Brian I. Rini(25), Frede Donskov(19), Sumanta K. Pal(17), Christian Kollmannsberger(15), Georg A. Bjarnason(15), Lori Wood(15), Wanling Xie(14), Jennifer J. Knox(13), Ulka N. Vaishampayan(13), Jae‐Lyun Lee(12), Sandy Srinivas(12), David F. McDermott(11), Neeraj Agarwal(11), Takeshi Yuasa(11), Sun Young Rha(9), Benoit Beuselinck(9), J. Connor Wells(9), Sabina Signoretti(7), Scott North(7)